Last quarter (Q3 2022), Gemini Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Gemini Therapeutics's net income was $-3.28M. See Gemini Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20
Total Revenue	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-
Gross Profit	-	-	-
Operating Expense	$ 43.89M	$ 69.00M	$ 34.04M
Operating Income	$ -43.89M	$ -69.00M	$ -34.04M
Net Non Operating Interest Income Expense	$ 421.00K	$ -2.14M	$ -6.79M
Other Income Expense	$ 48.00K	$ -724.00K	$ -8.00K
Pretax Income	$ -43.42M	$ -71.87M	$ -40.84M
Tax Provision	-	-	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-
Net Income Common Stockholders	$ -43.42M	$ -71.87M	$ -40.84M
Basic EPS	$ -1.00	$ -1.78	$ -2.70
Diluted EPS	$ -1.00	$ -1.78	$ -2.70
Basic Average Shares	$ 172.87M	$ 40.36M	$ 15.12M
Diluted Average Shares	$ 172.87M	$ 40.36M	$ 15.12M
Dividend Per Share	-	-	-
Total Operating Income As Reported	-	-	-
Reported Normalized Basic E P S	-	-	-
Reported Normalized Diluted E P S	-	-	-
Rent Expense Supplemental	-	-	-
Total Expenses	$ 43.89M	$ 69.00M	$ 34.04M
Net Income From Continuing And Discontinued Operation	$ -43.42M	$ -71.87M	$ -40.84M
Normalized Income	$ -43.42M	$ -71.87M	$ -40.83M
Interest Expense	$ 240.00K	$ 2.16M	$ 6.83M
EBIT	$ -43.18M	$ -69.71M	$ -34.01M
EBITDA	$ -43.13M	$ -69.48M	$ -33.69M

Currency in USD

Gemini Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing